08:28 AM EST, 11/22/2024 (MT Newswires) -- Aptose Biosciences ( APTO ) , an oncology company, was at last look down 35% in premarket trading after it priced its public offering of up to 40 million units at US$0.20 each.

Aptose expects to receive US$8 million. The warrants will have an exercise price of US$0.25 per share, will be exercisable immediately and will expire five years from issue.

The offering is expected to close by Nov. 25.

Aptose was last seen at US$0.16 in New York trade.